Conference Track

Resistance and Management of Treatment-Experienced Patients

Source: CCO Official Conference Coverage of the 2006 International AIDS Conference

Capsule Summaries

HIV-1 Primary Drug Resistance, Particularly NNRTI Resistance, Becoming Increasingly More Common in Newly Diagnosed Canadians
Significant Levels of Preexisting Drug Resistance in Treatment-Naive Individuals With Non-B HIV-1 Subtypes in Cameroon
Diagnostic Study in Mexican Clinics Shows HIV Genotyping With Dried Blood Samples Possible
Combination Atazanavir/Ritonavir Therapy May Reduce Prevalence of I50L Mutation at Virologic Failure
NRTIs Likely Contribute Little Virologic Activity to Salvage Regimens
Better Outcomes With Lamivudine Monotherapy vs Treatment Interruption in Patients Failing Lamivudine-Based HAART
Small Pilot Study Suggests Salvage Regimens Containing Etravirine and Darunavir/Ritonavir Possible Option for Highly Experienced Patients
Transmitted Drug Resistance Observed in 9% of Newly Diagnosed, Antiretroviral-Naive HIV-Positive Patients From European Surveillance Cohort
POWER 1 and 2 Studies: Twice-Daily Darunavir/Ritonavir Effective and Well Tolerated in Multidrug-Experienced Patients at 48 Weeks
POWER Studies Show High-Dose Darunavir (TMC114)/Ritonavir Well Tolerated in Treatment–Experienced Patients

Expert Analysis

Resistance and Management of Treatment-Experienced Patients

Faculty:
Charles Boucher, MD, PhD Kathleen E. Squires, MD Mark A. Wainberg, PhD
Andrew R. Zolopa, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss studies regarding the transmission of drug-resistant HIV
Describe recent data on the use of darunavir/ritonavir in treatment-experienced patients
Review new findings regarding the contribution of NRTIs and NNRTIs to virologic suppression in triple-class–experienced patients

CME CREDIT INFORMATION

Release Date: 09/29/06

Expiration Date: 09/28/07

Physicians: maximum of 1 AMA PRA Category 1 Credit(s)™

Pharmacists: 1 contact hour (0.1 CEUs)

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.